482 related articles for article (PubMed ID: 24816806)
1. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
2. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
3. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
Morales L; Pans S; Verschueren K; Van Calster B; Paridaens R; Westhovens R; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
J Clin Oncol; 2008 Jul; 26(19):3147-52. PubMed ID: 18474874
[TBL] [Abstract][Full Text] [Related]
4. Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation.
Henry NL; Speth K; Lintermans A; Kidwell KM; Carlson R; Hayes DF; Neven P
Clin Breast Cancer; 2017 Aug; 17(5):350-355.e4. PubMed ID: 28365336
[TBL] [Abstract][Full Text] [Related]
5. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
Lintermans A; Laenen A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
Ann Oncol; 2013 Feb; 24(2):350-355. PubMed ID: 23038762
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Lintermans A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
Ann Oncol; 2011 Aug; 22(8):1763-9. PubMed ID: 21273342
[TBL] [Abstract][Full Text] [Related]
7. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
Frechette D; Paquet L; Verma S; Clemons M; Wheatley-Price P; Gertler SZ; Song X; Graham N; Dent S
Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
[TBL] [Abstract][Full Text] [Related]
8. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
10. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
11. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
12. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
[TBL] [Abstract][Full Text] [Related]
13. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
Singer O; Cigler T; Moore AB; Levine AB; Hentel K; Belfi L; Do HT; Mandl LA
Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1910-8. PubMed ID: 22730307
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Mayer EL; Burstein HJ
Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
[TBL] [Abstract][Full Text] [Related]
16. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant aromatase inhibitor therapy in patients with stage I breast cancer at a regional oncology center in Israel: implementation of a 'switching' policy in postmenopausal patients after initial tamoxifen.
Geffen DB; Tokar M; Abu-Ghanem S; Braunstein R; Koretz M; Amir N; Delgado B; Sion-Vardi N; Ariad S; Lazarev I
Oncology; 2013; 85(3):145-52. PubMed ID: 23988814
[TBL] [Abstract][Full Text] [Related]
18. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
19. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
20. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]